静脉血栓栓塞（VTE）是癌症患者发病和死亡的主要原因。人们不断寻找能够预测癌症相关 VTE 的生物标志物。其中，凝血酶生成标记物提供了一个可能的选择。本系统综述检查了三种广泛使用的凝血酶生成生物标志物：凝血酶原片段 1.2 (F1.2)、凝血酶-抗凝血酶复合物 (TAT) 和离体凝血酶生成，预测实体和血液成人癌症患者 VTE 的能力。相关研究已在 PubMed 和 Embase 数据库中确定，且审查符合系统审查和荟萃分析指南的首选报告项目。每项研究均使用国家心肺血液研究所的质量评估工具进行评估。审查方案发布在 PROSPERO 上，标识符为 CRD42022362339。综述中总共纳入了 24 篇论文：11 篇报告了 F1.2 的数据，9 篇报告了 TAT 数据，12 篇报告了离体凝血酶生成数据。纳入研究的质量评级从良好（n = 13）、一般（n = 8）到差（n = 3）不等，具有高度异质性。然而，F1.2、TAT 复合物和离体凝血酶生成均被发现与 VTE 的发生有关。这种关联对于 F1.2 最为明显。此外，F1.2的确定能够提高几个既定风险评估分数的精确度。总之，发现患有 VTE 的癌症患者中凝血酶生成标记物升高，特别是 F1.2 被发现是癌症相关 VTE 的有希望的预测因子。Thieme。版权所有。

Venous thromboembolism (VTE) is a main contributor to morbidity and mortality in cancer patients. Biomarkers with the potential to predict cancer-associated VTE are continually sought. Of these, markers of thrombin generation present a likely option. The present systematic review examines the ability of three widely used biomarkers of thrombin generation: prothrombin fragment 1.2 (F1.2), thrombin-antithrombin complex (TAT), and ex vivo thrombin generation, to predict VTE in both solid and hematologic adult cancer patients. Relevant studies were identified in the PubMed and Embase databases, and the review conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Each study was evaluated using the quality assessment tool from the National Heart, Lung, and Blood Institute. The review protocol was published on PROSPERO with identifier CRD42022362339. In total, 24 papers were included in the review: 11 reporting data on F1.2, 9 on TAT, and 12 on ex vivo thrombin generation. The quality ratings of the included studies varied from good (n = 13), fair (n = 8), to poor (n = 3) with a high heterogenicity. However, F1.2, TAT complex, and ex vivo thrombin generation were all found to be associated with the development of VTE. This association was most pronounced for F1.2. Furthermore, the determination of F1.2 was able to improve the precision of several established risk assessment scores. In conclusion, markers of thrombin generation were found to be elevated in cancer patients with VTE, and particularly, F1.2 was found to be a promising predictor of cancer-associated VTE.Thieme. All rights reserved.